Entscheidungsfindung bei der Therapie des fortgeschrittenen Harnblasenkarzinoms
作者： K. Junker , A. Hartmann , M. Stöckle
DOI: 10.1007/S00120-012-2898-2
关键词:
摘要: Die Prognose von Patienten mit fortgeschrittenem Harnblasenkarzinom wird nach wie vor durch die systemische Dissemination bestimmt. Verbesserungen der Lymphknotenausraumung und perioperative Chemotherapie waren bislang wesentlichen Ansatze zur Verbesserung Prognose. Ergebnisse neoadjuvanten oder adjuvanten Therapie werden jedoch kontrovers diskutiert: auf einen Seite ubertherapiert, andererseits erhalten keine Therapie, deren Progressionsrisiko aufgrund eines gunstig erscheinenden Tumorstadiums unterschatzt wird.
springer.com
sci-hub.se 参考文章(38)
Steven Christopher Smith, Alexander Spyridon Baras, Garrett Dancik, Yuanbin Ru, Kuan-Fu Ding, Christopher A Moskaluk, Yves Fradet, Jan Lehmann, Michael Stöckle, Arndt Hartmann, Jae K Lee, Dan Theodorescu, A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment Lancet Oncology. ,vol. 12, pp. 137- 143 ,(2011) , 10.1016/S1470-2045(10)70296-5
DC Tomlinson, O Baldo, P Harnden, MA Knowles, FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer The Journal of Pathology. ,vol. 213, pp. 91- 98 ,(2007) , 10.1002/PATH.2207
Ruth L. Vinall, Alexandra Z. Ripoll, Sisi Wang, Chong-Xian Pan, Ralph W. deVere White, MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status International Journal of Cancer. ,vol. 130, pp. 2526- 2538 ,(2012) , 10.1002/IJC.26256
Kristy R. Kutanzi, Olga V. Yurchenko, Frederick A. Beland, Vasyl’ F. Checkhun, Igor P. Pogribny, MicroRNA-mediated drug resistance in breast cancer Clinical Epigenetics. ,vol. 2, pp. 171- 185 ,(2011) , 10.1007/S13148-011-0040-8
Junqing Chen, Wei Tian, Hongke Cai, Haifei He, Yongchuan Deng, Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer Medical Oncology. ,vol. 29, pp. 2527- 2534 ,(2012) , 10.1007/S12032-011-0117-4
Harman M. Bruins, George J. Huang, Jie Cai, Donald G. Skinner, John P. Stein, David F. Penson, Clinical Outcomes and Recurrence Predictors of Lymph Node Positive Urothelial Cancer After Cystectomy Journal of Urology. ,vol. 182, pp. 2182- 2187 ,(2009) , 10.1016/J.JURO.2009.07.017
Yuanbin Ru, Garrett M. Dancik, Dan Theodorescu, Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Current Opinion in Urology. ,vol. 21, pp. 420- 427 ,(2011) , 10.1097/MOU.0B013E32834956D6
Christoph Wiesner, Alice Salzer, Christian Thomas, Claudia Gellermann-Schultes, Rolf Gillitzer, Christian Hampel, Joachim W. Thüroff, Cancer‐specific survival after radical cystectomy and standardized extended lymphadenectomy for node‐positive bladder cancer: prediction by lymph node positivity and density BJUI. ,vol. 104, pp. 331- 335 ,(2009) , 10.1111/J.1464-410X.2009.08403.X
Roland B. Walter, Ted A. Gooley, Vincent H. J. van der Velden, Michael R. Loken, Jacques J. M. van Dongen, David A. Flowers, Irwin D. Bernstein, Frederick R. Appelbaum, CD33 expression and P-glycoprotein–mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy Blood. ,vol. 109, pp. 4168- 4170 ,(2007) , 10.1182/BLOOD-2006-09-047399
Johanna M. Pellikainen, Veli-Matti Kosma, Activator protein-2 in carcinogenesis with a special reference to breast cancer-A mini review International Journal of Cancer. ,vol. 120, pp. 2061- 2067 ,(2007) , 10.1002/IJC.22648